High ELF3 expression was associated with poor overall survival (OS) in NSCLC patients (log-rank p = 4.65E-04), an association which improved in Stage I patients (log-rank p = 2.30E-05) (Fig. 6). Here, ELF3 is linked to non-small cell lung carcinoma.